Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Mucinous ovarian tumor survival rates stress correct diagnosis

Key clinical point: Women with invasive, well-differentiated mucinous ovarian cancer are more likely to die from their disease within 10 years of diagnosis than women with mucinous borderline ovarian tumors, which highlights the importance of an accurate histopathologic diagnosis.

Major finding: The 10-year cause-specific survival of mucinous ovarian cancer was 92.7%, compared with 97.5% for borderline ovarian tumors (hazard ratio, 2.03; P = .007).

Study details: A retrospective study that analyzed data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program from 1988 to 2000.

Disclosures: The study was funded by Ensign Endowment for Gynecologic Cancer Research. The investigators reported financial relationships with KIYATEC, BioPath, M-Trap, and Chugai.

Citation:

Matsuo K et al. Gynecol Oncol. 2019 Feb 20. doi: 10.1016/j.ygyno.2019.02.003.